US legislation headache for Medicare plans

31 August 2008

The Democratic-controlled US Congress' over-ride of President George W Bush's veto of HR6331 has created compliance difficulties for Medicare Advantage and Part D prescription drug plans. With a deadline of August 30 to file operational riders, plans and notifications with the Centers for Medicare and Medicaid Services (CMS), the imposition of new regulations has caused a rush to amend marketing materials and customer relationship management systems.

The health care and drug plan providers are limited to a four-and-a-half-month window of opportunity to promote their products to potential customers. According to MedicareCRM, a firm which has clients in the top 10 Medicare Advantage plans in the USA, firms need to be aware that, despite a formal 2011 deadline for meeting the new restrictions, the CMS has indicated it will monitor and publicize cases where firms do not comply in the near future.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight